- Jerald P. Radich, MD,
- Michael Deininger, MD, PhD,
- Camille N. Abboud, MD,
- Jessica K. Altman, MD,
- Ellin Berman, MD,
- Ravi Bhatia, MD,
- Bhavana Bhatnagar, DO,
- Peter Curtin, MD,
- Daniel J. DeAngelo, MD, PhD,
- Jason Gotlib, MD, MS,
- Gabriela Hobbs, MD,
- Madan Jagasia, MD,
- Hagop M. Kantarjian, MD,
- Lori Maness, MD,
- Leland Metheny, MD,
- Joseph O. Moore, MD,
- Arnel Pallera, MD,
- Philip Pancari, MD,
- Mrinal Patnaik, MD,
- Enkhtsetseg Purev, MD, PhD,
- Michal G. Rose, MD,
- Neil P. Shah, MD, PhD,
- B. Douglas Smith, MD,
- David S. Snyder, MD,
- Kendra L. Sweet, MD, MS,
- Moshe Talpaz, MD,
- James Thompson, MD,
- David T. Yang, MD,
- Kristina M. Gregory, RN, MSN, OCN and
- Hema Sundar, PhD
Abstract
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient’s age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.
Footnotes
-
Please Note
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Chronic Myeloid Leukemia are not printed in this issue of JNCCN but can be accessed online at NCCN.org.
© National Comprehensive Cancer Network, Inc. 2018, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
-
Disclosures for the NCCN Chronic Myeloid Leukemia Panel
At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.
Individual disclosures for the NCCN Chronic Myeloid Leukemia Panel members can be found on page 1135. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)
These guidelines are also available on the Internet. For the latest update, visit NCCN.org.
-
NCCN Chronic Myeloid Leukemia Panel Members
*Jerald P. Radich, MD/Chairξ†
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
*Michael Deininger, MD, PhD/Vice Chair‡ξ
Huntsman Cancer Institute at the University of Utah
Camille N. Abboud, MD‡ξÞ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Jessica K. Altman, MD‡
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Ellin Berman, MD‡†Þ
Memorial Sloan Kettering Cancer Center
Ravi Bhatia, MD‡
University of Alabama at Birmingham Comprehensive Cancer Center
Bhavana Bhatnagar, DO‡†Þ
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Peter Curtin, MD‡ξ
UC San Diego Moores Cancer Center
Daniel J. DeAngelo, MD, PhD‡†
Dana-Farber/Brigham and Women’s Cancer Center
Jason Gotlib, MD, MS‡†
Stanford Cancer Institute
Gabriela Hobbs, MD‡†
Massachusetts General Hospital Cancer Center
Madan Jagasia, MD‡ξ
Vanderbilt-Ingram Cancer Center
Hagop M. Kantarjian, MD‡†Þ
The University of Texas MD Anderson Cancer Center
Lori Maness, MD‡
Fred & Pamela Buffett Cancer Center
Leland Metheny, MD‡ξ
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Joseph O. Moore, MD†
Duke Cancer Institute
Arnel Pallera, MD‡†
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
Philip Pancari, MD‡
Fox Chase Cancer Center
Mrinal Patnaik, MDξ
Mayo Clinic Cancer Center
Enkhtsetseg Purev, MD, PhD‡
University of Colorado Cancer Center
Michal G. Rose, MD†
Yale Cancer Center/Smilow Cancer Hospital
Neil P. Shah, MD, PhD‡
UCSF Helen Diller Family Comprehensive Cancer Center
B. Douglas Smith, MD†Þ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
David S. Snyder, MD‡ξ
City of Hope Comprehensive Cancer Center
Kendra L. Sweet, MD, MS‡†Þ
Moffitt Cancer Center
Moshe Talpaz, MD†
University of Michigan Rogel Cancer Center
James Thompson, MD‡
Roswell Park Comprehensive Cancer Center
David T. Yang, MD≠
University of Wisconsin Carbone Cancer Center
NCCN Staff: Kristina M. Gregory, RN, MSN, OCN, and Hema Sundar, PhD
KEY:
*Discussion Section Writing Committee
Specialties: ‡Hematology/Hematology Oncology; †Medical Oncology; ÞInternal Medicine; ≠Pathology; ξBone Marrow Transplantation
- Copyright © 2018 by the National Comprehensive Cancer Network
